Fig. 1

Yield of CD34+ cells and changes in white blood cell counts based on the mobilization method. a Data from 173 patients diagnosed with lymphoma who underwent peripheral blood stem cell collection (G-CSF only, n = 33; cyclophosphamide + G-CSF, n = 24; etoposide + G-CSF, n = 116) were analyzed. The highest yield of CD34+ cells was observed for etoposide + G-CSF [(1st day: G-CSF only: 1.36 (0.01–14.60); cyclophosphamide + G-CSF, 0.81 (0.05–18.70); etoposide + G-CSF, 4.32 (0.03–32.77), 2nd day: G-CSF-only, 0.96 (0.09–7.25); cyclophosphamide + G-CSF, 0.70 (0.06–13.20); etoposide + G-CSF, 3.37 (0.14–32.60), Total: G-CSF only, 3.13 (0.01–14.60); cyclophosphamide + G-CSF, 2.05 (0.12–31.9); etoposide + G-CSF, 7.22 (0.18–59.20)]. b The change in white blood cell (WBC) counts at the nadir and at the time of collection during mobilization was the lowest for the etoposide + G-CSF group among the three groups (∆WBC: G-CSF only, 15,305 (− 1412–574,000); cyclophosphamide + G-CSF, 10,320 (916–70,884); etoposide + G-CSF, 3770 (254–120,780)). Note: ‘At the nadir’ refers to the lowest WBC value during chemotherapy before peripheral blood stem cell collection. ‘∆WBC’ refers to the increase in WBC counts from the nadir to the time of peripheral blood stem cell collection. Note: *** p < 0.001 after Bonferroni correction; ** p < 0.01 after Bonferroni correction. Note: Values are reported as the median with range. Abbreviations: G-CSF, granulocyte colony-stimulating factor; CY, cyclophosphamide; ETO, etoposide